Wockhardt FY 25 EBITDA Jumps to Rs.418 Crore; 67% Growth, Novel Antibiotics Zaynich® and Miqnaf Approved and Launched

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4th Quarter Results for Financial Year 2024-25. The company saw a YoY growth of 5% in revenue in FY25, with revenue for FY25 of INR 3,033 Cr compared to INR 2,879 Cr in the previous year. YoY growth of 67% in EBITDA in FY25, EBITDA for FY25 of INR 418 Cr compared to INR 251 Cr in the previous year. The company also announced the approval and launch of novel antibiotics Zaynich® and Miqnaf. Zaynich® has demonstrated the highest-ever efficacy achieving a clinical cure rate of 96.8% in a global, pivotal, registration-enabling, Phase Ill study. Miqnaf, India’s First Indigenous Respiratory Antibiotic, was launched on May 27 2025, addressing a leading global cause of death, which claims over 2 million lives annually.